Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.30 0.0%	$117.02	$73.04 ▼ $129.49	$8.35B	0.89	1.39 million shs	3.57 million shs
EBS Emergent Biosolutions	$7.34 +0.1%	$6.40	$4.02 ▼ $15.10	$399.49M	2.09	1.70 million shs	1.05 million shs
EVTCY Evotec	$4.07 -2.4%	$4.13	$14.22 ▼ $26.57	$1.34B	0.98	2,407 shs	29,351 shs
FOLD Amicus Therapeutics	$6.09 -3.3%	$6.07	$5.51 ▼ $12.65	$1.88B	0.51	3.23 million shs	2.56 million shs
PRGO Perrigo	$27.52 +0.9%	$26.71	$23.14 ▼ $30.93	$3.78B	0.45	1.44 million shs	1.08 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	+0.80%	+0.85%	+59.95%	+11.51%
EBS Emergent Biosolutions	0.00%	+5.01%	+11.04%	+67.92%	-20.99%
EVTCY Evotec	-2.40%	-3.10%	-4.68%	+27.99%	-20.51%
FOLD Amicus Therapeutics	0.00%	-1.06%	-1.30%	-6.02%	-41.05%
PRGO Perrigo	0.00%	+1.18%	+1.10%	+11.91%	+1.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.2225 of 5 stars	2.1	2.0	0.0	0.0	2.9	0.8	0.6
EBS Emergent Biosolutions	4.2428 of 5 stars	3.5	1.0	0.0	4.6	1.9	2.5	1.3
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	4.1387 of 5 stars	3.4	1.0	0.0	4.3	3.2	0.0	1.9
PRGO Perrigo	4.4959 of 5 stars	2.1	2.0	4.2	3.5	2.1	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.81% Downside
EBS Emergent Biosolutions	3.00	Buy	$14.33	95.28% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	166.37% Upside
PRGO Perrigo	2.25	Hold	$33.00	19.91% Upside

Current Analyst Ratings Breakdown

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	16.41	N/A	N/A	$4.70 per share	27.51
EBS Emergent Biosolutions	$1.04B	0.38	$1.92 per share	3.83	$8.91 per share	0.82
EVTCY Evotec	$572.16M	2.35	$0.04 per share	105.53	$2.52 per share	1.62
FOLD Amicus Therapeutics	$528.29M	3.55	N/A	N/A	$0.65 per share	9.37
PRGO Perrigo	$4.37B	0.87	$5.05 per share	5.45	$31.66 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	198.92	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.55	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	9.93	∞	N/A	20.85%	16.02%	7.81%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.16	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.99	N/A	-4.16%	8.93%	3.87%	8/1/2025 (Estimated)

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/5/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
8/1/2025	Q2 2025	PRGO Perrigo	$0.59	N/A	N/A	N/A	$1.08 billion	N/A
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.22%	N/A	N/A	23 Years

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
EBS Emergent Biosolutions	1.20	6.32	3.51
EVTCY Evotec	0.53	2.57	2.50
FOLD Amicus Therapeutics	2.02	3.34	2.47
PRGO Perrigo	0.82	2.36	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
EBS Emergent Biosolutions	78.40%
EVTCY Evotec	N/A
FOLD Amicus Therapeutics	N/A
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
EBS Emergent Biosolutions	1.20%
EVTCY Evotec	N/A
FOLD Amicus Therapeutics	2.20%
PRGO Perrigo	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
PRGO Perrigo	8,379	137.48 million	136.52 million	Optionable

EBS, BPMC, FOLD, PRGO, and EVTCY Headlines

Recent News About These Companies

PRGO - Perrigo Co PLC Key Metrics - Morningstar

July 9, 2025 | morningstar.comM

Should Value Investors Buy Perrigo (PRGO) Stock?

July 9, 2025 | zacks.com

D.A. Davidson & CO. Purchases Shares of 57,736 Perrigo Company plc (NYSE:PRGO)

July 8, 2025 | marketbeat.com

DAVENPORT & Co LLC Cuts Stake in Perrigo Company plc (NYSE:PRGO)

July 8, 2025 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Shares Sold by KBC Group NV

July 7, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Upgraded at Wall Street Zen

July 6, 2025 | americanbankingnews.com

Perrigo (NYSE:PRGO) Upgraded by Wall Street Zen to "Buy" Rating

July 5, 2025 | marketbeat.com

Summit Trail Advisors LLC Takes $386,000 Position in Perrigo Company plc (NYSE:PRGO)

July 3, 2025 | marketbeat.com

Perrigo Announces Leadership Change Amid Strategic Update

July 1, 2025 | tipranks.com

Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance

July 1, 2025 | prnewswire.com

Good Start® | Dr. Brown's™ Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby

July 1, 2025 | prnewswire.com

Allspring Global Investments Holdings LLC Has $31.65 Million Position in Perrigo Company plc (NYSE:PRGO)

July 1, 2025 | marketbeat.com

Copeland Capital Management LLC Has $68.78 Million Position in Perrigo Company plc (NYSE:PRGO)

June 28, 2025 | marketbeat.com

Wall Street Zen Downgrades Perrigo (NYSE:PRGO) to Hold

June 27, 2025 | marketbeat.com

Perpetual Ltd Sells 486,454 Shares of Perrigo Company plc (NYSE:PRGO)

June 27, 2025 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Shares Sold by Janney Montgomery Scott LLC

June 27, 2025 | marketbeat.com

Boyar Asset Management Inc. Takes $734,000 Position in Perrigo Company plc (NYSE:PRGO)

June 26, 2025 | marketbeat.com

Lecap Asset Management Ltd. Takes $724,000 Position in Perrigo Company plc (NYSE:PRGO)

June 26, 2025 | marketbeat.com

PRGO - Perrigo Co PLC Chart - Morningstar

June 25, 2025 | morningstar.comM

Should Value Investors Buy Perrigo (PRGO) Stock?

June 23, 2025 | zacks.com

February 2026 Options Now Available For Perrigo (PRGO)

June 20, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside

EBS, BPMC, FOLD, PRGO, and EVTCY Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$129.30 -0.03 (-0.02%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$129.30 0.00 (0.00%)

As of 07/11/2025 05:23 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Emergent Biosolutions NYSE:EBS

$7.34 +0.01 (+0.14%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$7.28 -0.06 (-0.76%)

As of 07/11/2025 07:50 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Evotec OTCMKTS:EVTCY

$4.07 -0.10 (-2.40%)

As of 07/11/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Amicus Therapeutics NASDAQ:FOLD

$6.09 -0.21 (-3.33%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$6.24 +0.15 (+2.45%)

As of 07/11/2025 05:41 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Perrigo NYSE:PRGO

$27.52 +0.25 (+0.92%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$27.21 -0.31 (-1.13%)

As of 07/11/2025 07:34 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Earnings

Compare Dividends

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EBS, BPMC, FOLD, PRGO, and EVTCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EBS, BPMC, FOLD, PRGO, and EVTCY Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Emergent Biosolutions NYSE:EBS

Evotec OTCMKTS:EVTCY

Amicus Therapeutics NASDAQ:FOLD

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools